[1]周家香,吴春芝,冯 芳,等.康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌患者免疫功能和肿瘤标志物的影响[J].陕西医学杂志,2024,(6):818-822.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.021]
　ZHOU Jiaxiang,WU Chunzhi,FENG Fang,et al.Effects of kanglaite intravenous injection combined with cisplatin perfusion on immune function and tumor markers in patients with advanced NSCLC[J].,2024,(6):818-822.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.021]
点击复制

康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌患者免疫功能和肿瘤标志物的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年6期
页码:
818-822
栏目:
药物与临床
出版日期:
2024-06-05

文章信息/Info

Title:
Effects of kanglaite intravenous injection combined with cisplatin perfusion on immune function and tumor markers in patients with advanced NSCLC
作者:
周家香; 吴春芝; 冯 芳; 薛登梅
(成都市第六人民医院肿瘤科,四川 成都 610051)
Author(s):
ZHOU Jiaxiang; WU Chunzhi; FENG Fang; XUE Dengmei
(Department of Oncology,the Sixth People's Hospital of Chengdu,Chengdu 610051,China)
关键词:
非小细胞肺癌;  康莱特;  顺铂;  免疫功能;  肿瘤标志物;  不良反应
Keywords:
Non-small cell lung cancer;  Kanglaite;  Cisplatin;  Immune function;  Tumor markers;  Adverse reactions
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2024.06.021
文献标志码:
A
摘要:
目的:探究康莱特静脉注射联合顺铂灌注对晚期非小细胞肺癌(NSCLC)患者免疫功能和肿瘤标志物的影响。方法:选取于接受治疗的Ⅲb-Ⅳ期NSCLC患者124例为研究对象,入院编号后经单双号法分为顺铂组(单号,62例,给予顺铂胸腔灌注方案化疗)和康莱特组(双号,62例,给予康莱特联合顺铂胸腔灌注方案)。治疗4个疗程后,比较两组客观缓解率(ORR)和疾病控制率(DCR)、治疗前后甲胎蛋白(AFP)、癌胚抗原(CEA)和癌抗原125(CA125)及免疫球蛋白(IgG、IgA、IgM)和T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)水平变化。记录药物不良反应发生情况。结果:化疗4个疗程后,两组ORR比较无统计学差异(P>0.05),康莱特组DCR显著高于顺铂组(P<0.05); 两组AFP、CEA、CA125水平降低,且康莱特组低于顺铂组(均P<0.05); 康莱特组IgG、IgA、IgM水平降低,顺铂组IgA水平降低,且康莱特组低于顺铂组(均P<0.05); 康莱特组CD3+、CD4+/CD8+水平降低,CD4+水平显著升高,顺铂组CD4+/CD8+水平升高,且康莱特组CD3+、CD4+/CD8+水平低于顺铂组,CD4+水平高于顺铂组(均P<0.05); 康莱特组恶心呕吐、泌尿系统损伤发生率低于顺铂组(均P<0.05)。结论:康莱特静脉注射联合顺铂灌注化疗可抑制晚期NSCLC患者肿瘤生长,降低肿瘤标志物水平,提高机体免疫功能,降低化疗不良反应,安全性较好。
Abstract:
Objective:To investigate the effect of kanglaite intravenous injection combined with cisplatin perfusion on immune function and tumor markers in patients with advanced non-small cell lung cancer(NSCLC).Methods:A total of 124 patients with stage Ⅲb-Ⅳ NSCLC who received treatment were selected as the study subjects.After admission,they were divided into cisplatin group(odd number,62 cases,treated with cisplatin intrapleural perfusion chemotherapy)and kanglaite group(even number,62 cases,treated with kanglaite combined with cisplatin intrapleural perfusion chemotherapy)by odd and even number method.After four courses of treatment,the objective response rate(ORR)and disease control rate(DC),alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA)and cancer antigen 125(CA125),immune function indexes(IgG,IgA,IgM,CD3+,CD4+and CD4+/CD8+)before and after treatment were compared between the two groups.The occurrence of adverse drug reactions was recorded.Results: After 4 courses of chemotherapy,there was no significant difference in ORR between the two groups(P>0.05),while the DCR in the kanglaite group was significantly higher than that in the cisplatin group(P<0.05); the levels of AFP,CEA and CA125 in the two groups were decreased,and those in the kanglaite group were lower than those in the cisplatin group(all P<0.05); the levels of IgG,IgA and IgM in the kanglaite group were decreased,and the level of IgA in the cisplatin group was decreased,and the level of IgA in the kanglaite group was lower than that in the cisplatin group(all P<0.05); the levels of CD3+ and CD4+/CD8+ in kanglaite group were declined,while the level of CD4+ was significantly risen,and the level of CD4+/CD8+ was significantly elevated,and the levels of CD3+ and CD4+/CD8+ in kanglaite group were significantly lower and the level of CD4+ was higher compared to cisplatin group(all P<0.05); the incidence of nausea and vomiting and urinary system injury in the kanglaite group was lower than that in the cisplatin group(all P<0.05).Conclusion:Kanglaite intravenous injection combined with cisplatin chemotherapy can inhibit tumor growth in patients with advanced NSCLC,reduce the levels of tumor markers,improve the immune function of the body,and reduce the adverse reactions of chemotherapy,with good safety.

参考文献/References:

[1] 滕鑫,杨正轩,王媛,等.miR-96-5p靶向PTEN激活PI3K-Akt信号通路抑制非小细胞肺癌细胞增殖、迁移和侵袭实验研究[J].陕西医学杂志,2023,52(11):1511-1516.
[2] 王军徽,肖萌,马功贤,等.非小细胞肺癌中医药治疗研究进展[J].陕西中医,2023,44(11):1663-1665.
[3] 姜桔红,李玉勤,顾莹莹.晚期非小细胞肺癌免疫检查点抑制剂相关性肌炎的临床病理学特征[J].中华结核和呼吸杂志,2022,45(1):47-52.
[4] 韩森,马旭,聂鋆,等.晚期肺神经内分泌肿瘤伊立替康联合/不联合顺铂化疗的初步临床观察[J].中华肿瘤防治杂志,2021,28(9):694-698.
[5] 孟令武,李志彬,崔杰.经导管肝动脉化疗栓塞联合康莱特注射液对原发性肝癌患者瘤体体积及生活质量的影响[J].世界中西医结合杂志,2020,15(4):727-730.
[6] HUANG X,WANG J,LIN W,et al.Kanglaite injection plus platinum-based chemotherapy for stage Ⅲ/Ⅳ non-small cell lung cancer:A meta-analysis of 27 RCTs[J].Phytomedicine,2020,67:153154.
[7] JAZIEH A R,ZEITOUNI M,ALGHAMDI M,et al.Management guidelines for stage Ⅲ non-small cell lung cancer[J].Crit Rev Oncol Hematol,2020,157:103144.
[8] 中国抗癌协会肺癌专业委员会,中华医学会肿瘤学分会肺癌学组.Ⅲ期非小细胞肺癌多学科诊疗专家共识(2019版)[J].中华肿瘤杂志,2019,41(12):881-890.
[9] 皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤,2012,32(2):142-144.
[10] 肖凌,王洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医,2021,42(12):1696-1699.
[11] 高娜,王崇宝.胸腺肽联合顺铂、培美曲塞二钠治疗晚期非小细胞肺癌临床疗效研究[J].陕西医学杂志,2022,51(11):1424-1427.
[12] 周华妙,李妍,谷建钟,等.康莱特序贯治疗中晚期非小细胞肺癌临床疗效分析[J].中华中医药学刊,2020,38(7):248-251.
[13] 何严璐琦,刘贤明,任燕燕,等.康莱特注射液辅助治疗晚期无驱动基因非小细胞肺癌疗效观察[J].现代中西医结合杂志,2021,30(33):3655-3659.
[14] LIN B,WANG Q,LIU K,et al.Alpha-fetoprotein binding mucin and scavenger receptors:An available bio-target for treating cancer[J].Frontiers in Oncology,2021,11:625936.
[15] HING J X,MOK C W,TAN P T,et al.Clinical utility of tumour marker velocity of cancer antigen 15-3(CA15-3)and carcinoembryonic antigen(CEA)in breast cancer surveillance[J].Breast,2020,52:95-101.
[16] AGRAWAL S,GUPTA A,GUPTA S,et al.Role of carbohydrate antigen 19-9,carcinoembryonic antigen,and carbohydrate antigen 125 as the predictors of resectability and survival in the patients of carcinoma gall bladder[J].J Carcinog,2020,19:4.
[17] 马玥,王立芳,郑展,等.肺岩宁方联合顺铂对肺癌A549细胞生物学行为的影响[J].中华中医药杂志,2022,37(6):3452-3456.
[18] LU T,YU J,GAO R,et al.Chinese patent medicine kanglaite injection for non-small-cell lung cancer:An overview of systematic reviews[J].J Ethnopharmacol,2023,302:115814.
[19] WEN J,YANG T,WANG J,et al.Kanglaite injection combined with chemotherapy versus chemotherapy alone for the improvement of clinical efficacy and immune function in patients with advanced non-small-cell lung cancer:A systematic review and meta-analysis[J].Evid Based Complement Alternat Med,2020,2020:8586596.
[20] 郑静娴,王晓杰,余家密,等.贝伐珠单抗或重组人血管内皮抑制素联合顺铂胸腔灌注治疗肺腺癌恶性胸腔积液患者的临床研究[J].中国临床药理学杂志,2021,37(24):3311-3314.
[21] 黄坤林,张秀美,宋伟祥,等.中药辅助紫杉醇-顺铂方案经导管动脉灌注化疗治疗不可切除非小细胞肺癌的临床研究[J].介入放射学杂志,2021,30(2):136-139.
[22] 林卫佳,张亚平,李峰,等.重组人血管内皮抑制素注射液联合顺铂胸腔内灌注治疗肺癌恶性胸腔积液患者的临床研究[J].中国临床药理学杂志,2023,39(13):1836-1840.
[23] WANG D,XU Y,HUANG T,et al.Clinical efficacy and safety of NSCLC ancillary treatment with compound kushen injection through immunocompetence regulation:A systematic review and meta-analysis[J].Phytomedicine,2022,104:154315.
[24] KIM C G,KIM G,KIM K H,et al.Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer[J].J Immunother Cancer,2021,9(12):e002780.
[25] 桂雪梅,代丽,袁钦伟,等.康莱特注射液在化疗药物治疗晚期非小细胞肺癌中的作用及对CD3+、CD4+、NK、CD4+/CD8+水平的影响[J].中华中医药学刊,2020,38(5):147-150.
[26] 乔志安,杨立鑫,王晓贞,等.调强放疗联合康莱特注射液同期TP化疗对中晚期非小细胞肺癌临床疗效、免疫功能及不良反应的影响[J].中华中医药学刊,2020,38(5):207-211.
[27] CHEN C,AI Q D,WEI Y H.Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux[J].J Ethnopharmacol,2021,264:113388.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(6):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(6):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(6):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(6):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(6):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(6):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(6):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
基金项目:四川省卫生和计划生育委员会科研课题(17PJ407)
更新日期/Last Update: 2024-06-05